A multinational study by the LHON Study Group has reported sustained visual improvements and a favor...

Beacon Therapeutics has successfully raised $170 million in Series B funding, marking a significant ...

Ocugen has announced that the second phase of the OCU410 ArMaDa clinical trial will continue followi...

Atsena Therapeutics has announced the initiation of Part B of the LIGHTHOUSE study, a Phase 1/2 clin...

Researchers at the Broad Institute of MIT and Harvard have made a breakthrough in gene editing techn...

ViGeneron has announced significant progress for its gene therapy candidate VG901, aimed at treating...

Alkeus Pharmaceuticals has announced promising interim data from the TEASE-3 study, highlighting the...

In an innovative stride toward combating age-related macular degeneration (AMD), Oculogenex, Inc. ha...

AbbVie and Regenxbio have announced updates on the clinical development of ABBV-RGX-314, a potential...

Ocugen, Inc. has announced encouraging 2-year safety and efficacy results from its Phase 1/2 clinica...